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1  Introduction 
1.1 Definition of the term „depression“ 
 
When originally used in psychiatry, the term depression (Latin: deprimere = press 
or push down) had a much less specific meaning than today, i.e. it referred to a 
general prostration and an impairment of mental functio s. When the term was 
adopted into psychiatric nomenclature in the first half of the 19th century, it was 
initially used as a class heading for groups characte ised by sub-average mental 
functioning. Kraepelin (1913) used this term to denot  “melancholic or depressive 
conditions with sad or anxious mood and an impediment of thinking and acting” 
[author’s translation]. Since that time further attempts have been made to define 
the term, e.g. by Jaspers (1913, 1959) and Bleuler (1916) (Möller H-J. et al., 
2005a). In the 20th century the term manic-depressiv  psychosis increasingly 
gained acceptance and recently, the term affective psychoses. With the introduc-
tion of the new diagnosis and classification system ICD-10 and DSM-III-R 
(1987, 1991), the previous aetiopathogenetically oriented triadic classification 
system of organic and endogenous psychoses versus “ne roses, personality disor-
ders and other non-mental disorders” (ICD 9, DSM III, 1980) was done away 
with. The atheoretical, purely descriptive term “depressive episode” in ICD-10 or 
“major depression” in DSM-IV took the place of the classical differentiation be-
tween “endogenous” and “neurotic” depressions. The term “affective disorders” is 
used to refer to the whole group of these disorders. The ICD-10 classification of 
affective disorders is subdivided into manic episodes, bipolar affective disorder, 
depressive disorder (“major depression”), persistent affective disorder, recurrent 
brief depressive disorder (“minor depression”), other affective disorders and the 
unspecified affective disorders. 
The depressive disorders are by far the most important of the affective disorders. 
Today, they are among the most common mental disorders. Frequency rates de-
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pend on the sample and diagnosis criteria and differ between countries and cul-
tures. About 5%-10% of the German population (approx. 4 million people) are 
afflicted with depressions requiring treatment (point prevalence). Between 10% 
and 20% of people (8%-12% of men, 10%-25% of women) suffer from a depres-
sion at some time in their lives. A large German study found that the lifetime 
prevalence of a depressive disorder was 16.4% (men: 10.4%; women: 20.4%) 
(Statistisches Bundesamt, 1998). It is noteworthy that about 50% of people with 
depression do not consult a physician and about 50% of depressions are not rec-
ognised by general practitioners. The average age at onset is between 30 and 45 
years for unipolar depressions and 20 to 35 years for bipolar depressions. Late-life 
depression is the most common mental disorder among people over the age of 65. 
The prevalence is estimated to be at least 10% (Statistisches Bundesamt, 2010). 
 
 
1.2 Symptoms 
 
The World Health Organization (WHO) study “Global Burden of Disease 1990”  
found that depressions have a more negative effect on people’s quality of life than 
cardiovascular diseases and are predicted to be the second most important cause 
of disability in 2030 (Murray et al., 1997). 
The clinical picture of depression can take many forms. The leading symptoms are 
depressive mood, inhibited drive and thinking and sleep disorders. The degree of 
depression can range from slightly depressed mood t melancholic, seemingly 
hopeless and persistent inability to feel anything (“feeling of lack of feeling”). 
Other symptoms include loss of interest, inability to make decisions, anxiety, in-
ner restlessness, brooding and physical symptoms. Depressive patients have a 
pronounced suicide risk. Fifteen per cent of patients with a severe depressive dis-
order commit suicide, 20%-60% have suicide attempts in their medical history 
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and 40%-80% have suicidal thoughts during a depression. Depressed people have 
a negative view of themselves and the surrounding world, often become socially 
withdrawn and sometimes become strangers to themselves (self-alienation). 
Some patients can be recognised relatively easily on the basis of their outer ap-
pearance and quiet, hesitant voice. Such cases are differentiated into different sub-
types: inhibited depression, agitated depression, masked (somatic) depression and 
Sisi syndrome. 
 
 
1.3 Aetiology 
1.3.1 Genetics 
 
Adoption, twin and family studies have proven that genetic factors play a role in 
the occurrence of depressive disorders. Twin studies found a concordance rate of 
60% for recurrent depressive disorders. In adoption studies, the adopted offspring 
of depressive parents developed depression more frequently than the offspring of 
healthy parents. However, studies conducted in recent years were unable to clarify 
the type of inheritance. If the cause was a larger gene defect, a so-called “major 
gene effect”, with high penetrance, the concordance rate in identical twins should 
be a lot higher. For this reason, it is assumed that several genes are most likely 
involved, whose effects summate and, together with other factors, predispose to 
depression (Wehling, 2005). 
 
 
1.3.2 Biological rhythms 
 
Clinical observations indicated already early on that chronobiological factors play 
an important role. Some depressions are seasonal and occur more frequently in 
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spring or autumn: the existence of a special type of depression, so-called seasonal 
depression, was first recognised in the mid-1980s. This kind of depression occurs 
only in autumn or winter or both and is characterised by special, “atypical” symp-
toms (including increased appetite and need for sleep). 
The daily fluctuations and the nocturnal and early morning awakenings typical of 
“endogenous” depressions are signs of a disturbance of ircadian rhythm. Experi-
mental sleep research has shown that depressive patients show more light sleep 
stages and fewer deep sleep stages than healthy controls. They have a longer sleep 
onset latency, REM latency is reduced and various biological rhythms are desyn-
chronised. The antidepressive efficacy of sleep deprivation is assumed to be based 
on a resynchronisation (Möller H-J. et al., 2005b). 
 
 
1.3.3 Neuroendocrinology 
1.3.3.1 Hypothalamus-pituitary-adrenal axis 
 
A large percentage of depressive patients show abnormalities in tests such as the 
dexamethasone suppression test or dexamethasone/cortisol-releasing-hormone 
(CRH) test or show decreased adrenocorticotropin (ACTH) release, all of which 
reflect an overstimulation of the hypothalamus-pituitary-adrenal (HPA) axis. In 
contrast to the hypercortisolism caused by an adrenl tumour, in depression the 
overstimulation is caused by disturbances in CNS control. Dysfunctions in central 
glucocorticoid receptors are assumed to be responsible. Furthermore, research 
reports show that depressive patients have lower thyroid stimulating hormone 
(TSH) plasma concentrations and that the TSH response to thyrotropin releasing 
hormone (TRH) stimulation is decreased or TRH levels in the CNS are increased 
(Müller et al., 2005). 
The neuroendocrine reaction to stress is regulated by the HPA axis. The cascade 
starts in the CNS with increased CRH release by the hypothalamus. CRH stimu-
lates the pituitary to release ACTH, which in turn stimulates the synthesis of corti-
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sol in the adrenal cortex. In addition to this mechanism, arginine vasopressin 
(AVP), which is also released during stressful situat ons, is co-secreted (Scott et 
al., 1998). AVP also acts on e the pituitary and increases the release of ACTH 
through a synergistic effect with CRH. 
 
 
1.3.3.2 Hypothalamus-pituitary-thyroid axis 
 
Hypothyroidism was shown to cause major depression, which remitted after 
treatment with thyroxine (Bartalena et al., 1990). There is some evidence for a 
dysfunction of the hypothalamus-pituitary-thyroid (HPT) axis in depression. Thy-
roxine (T4) levels are increased in some depressive pati nts (Wahby et al., 1988) 
as a result of the effects of TSH on TRH (Wahby et al., 1988, Hein et al., 1990). 
T4 levels and the concentration of free T4 have been r ported to decrease after 
treatment with antidepressants (Gendall et al., 2003). 
 
 
1.3.4 Amine deficiency hypothesis 
 
For more than 20 years hypotheses have existed which suggest that depressive 
disorders are related to reductions in the neurotransmitters noradrenaline and sero-
tonin. Studies have shown that concentrations of noradrenaline and serotonin in 
particular are lower in depressive patients than in healthy controls. The main sup-
port for this hypothesis came from the clarification f the mode of action of anti-
depressants, which increase the concentration of amines in the synaptic cleft. Par-
ticularly noteworthy in this context are the tricyclic antidepressants (TCAs) and 
monoamine oxidase inhibitors (MAOIs) (Bunney et al., 1965, Schildkraut et al., 
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1965). However, this hypothesis does not explain either why 2 to 3 weeks of 
treatment are necessary to reduce depressive symptoms, although monoamines are 
replaced within one to two days, or why other substances such as cocaine or am-
phetamines (which promote serotonergic and noradrenergic transmission) are not 
effective in treating depressive patients (Sakash et al., 2002). Furthermore, the 
hypothesis cannot explain why antidepressants are effective in other dysfunctions 
such as social phobias (Sheehan et al., 1993) and why other drugs such as tian-
eptine are effective even though they are assumed to increase serotonin reuptake, 
i.e. they have the opposite effect to the antidepressant selective serotonin reuptake 
inhibitors (SSRI) (Loo et al., 1999, Pineyro et al., 1999, Wilde et al., 1995). There 
is also no explanation as to why the density of serotonin receptors increases after 
longer-term electroconvulsive therapy, one of the most effective treatments for 
depression (Butler et al., 1993).  
Despite these limitations, the amine deficiency hypothesis drove the development 
of safe antidepressants such as the SSRIs, which include citalopram, fluoxetine, 
fluvoxamine, paroxetine and setraline, the selectiv noradrenaline reuptake inhibi-
tors and the dual antidepressants such as venlafaxine and milnacipran, which 
modify both the noradrenergic and the serotonergic systems (Charney et al., 
1981).  
 
 
1.3.5 The role of inflammatory changes 
 
The macrophage theory is the first theory to address the role of the immune sys-
tem and inflammatory changes in the development of depression. In this hypothe-
sis, interleukin (IL) 1β, which is secreted by macrophages, directly stimulates the 
secretion of CRH by the hypothalamus and induces hyperactivity of the HPA axis. 
This is a link between the immune system, neuroendocrin logy and neurotrans-
mitter replacement in depressions. Acute infections in humans and animals have 
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been shown to be accompanied by a group of unspecific symptoms, i.e. fever, loss 
of appetite, hyperalgesia, hypersomnia, anhedonia ad depressive mood (Hart, 
1988). The release of proinflammatory cytokines such as IL-1β, IL-6 and tumour 
necrosis factor (TNF) α is an integrated part of the host response to infections. 
These cytokines play a central role in the interplay of neurotransmitters and the 
neuroendocrinological system. Stimulation of the HPA axis by IL-1 increases the 
secretion of ACTH by the pituitary and of glucocorticoids by the adrenal cortex 
(Tsagarakis et al., 1989). Evidence also exists that IL-1 increases the  in vivo 
turnover rate of serotonin in some regions of the rat b ain (Gemma et al., 1994). 
Furthermore, IL-1 activates the central noradrenergic system. For this reason, in 
rat models there is a measurable increase in the concentration of 3-methoxy-4-
hdroxyphenylglycol, a metabolite of noradrenaline (Dunn, 1988). 
Experiments have shown that a systemic injection of lip polysaccharides (LPS), a 
component of the cell walls of gram-negative bacteria, not only promotes the re-
lease of proinflammatory cytokines but also causes d pressions and “sickness 
behaviour” (Bluthe et al., 1999). Other studies have shown that interferon (IFN), a 
cytokine used in the treatment of cancer and virus infections, can also cause de-
pressions. When high doses of i.v. IFN-α were administered in short intervals, 
20%-60% of patients developed mental disorders. The symptoms remitted after 
discontinuation of the medication and a brief latency period of a few days (Iivana-
inen et al., 1985, Meyers et al., 1991, Poutiainen et al., 1994, Mattson et al., 1983, 
Rohatiner et al., 1983). In contrast to these severe side effects resulting from ad-
ministration of high doses, less severe neuropsychiatric effects are reported during 
treatment with lower doses. Also, the latency period is longer and only 4%-16% 
of patients experience side effects (Schaefer et al., 2002).  
Depressions have been proven to be associated with a defective regulation of im-
mune system mediators. In vitro studies have shown that when human monocytes 
are incubated with various antidepressants and LPS,noticeably less IL-1, IL-6 and 
TNF-α is released (Xia et al., 1996). Other studies have shown an increase in the 
anti-inflammatory cytokine IL-10 and a decrease in IFN-γ (Kubera et al., 2000a, 
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Kubera et al., 2000b). However, there is some controversy concerning the anti-
inflammatory effects of various antidepressants. In animal experiments, rats were 
infected with LPS; the subsequent symptoms such as weight loss, refusal to eat 
and decreased consumption of a saccharin solution could be treated by chronic 
treatment with tricyclic antidepressants, but not with venlafaxine or SSRIs (Shen 
et al., 1999). This finding is supported by another in vivo study in which desip-
ramine reduced the secretion of IL-1 and TNF-α after infection with LPS but no 
effects were seen with venlafaxine or paroxetine (Connor et al., 2000). In a rat 
model of olfactory bulbectomy, the increase of acute phase protein was found to 
be reduced by tricyclic antidepressants and SSRIs (Leonard et al., 2002). Fur-
thermore, SSRIs decreased the release of IL-6 and acute phase proteins in patients 
with depressions (Sluzewska et al., 1995). 
IL-1 indirectly increases the synthesis of prostaglandin E2 (PGE2), an inflamma-
tory mediator and cofactor in the expression of indoleamine 2,3-dioxygenase 
(IDO). An increased PGE2 concentration was measured in the saliva, blood and 
cerebrospinal fluid of depressive patients (Nishino et al., 1989, Calabrese et al., 
1986, Gerner et al., 1983). On the basis of these findings, the inhibitory function 
of antidepressants on cyclooxygenase (COX), which is responsible for the synthe-
sis of PGE2, is also being considered as a mechanism for their antidepressant ef-
fect, as inflammatory reactions are thus reduced (Lonard, 2001). 
Furthermore, in recent years interest has grown in the positive effect of proin-
flammatory cytokines on the enzyme IDO, which catabolises tryptophan and re-
sults in reduced synthesis of serotonin (Carlin et al., 1987, Carlin JM, 1987, Tay-
lor et al., 1991, Yasui et al., 1986). The involvement of proinflammatory 
cytokines in the pathophysiology of depressions has been clearly proven. Several 
mechanisms allow the cytokines to reach the target receptors in the brain from the 
peripheral blood, including active transport, transport via the circumventricular 
organs, transport by binding to receptors in the blood vessels that supply the brain 
and retrograde transport of cytokines along the vagus nerve (Maier et al., 2003). 
These proinflammatory cytokines have a protective and  degenerative effect on 
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neurones and glial cells, depending on the concentration and the duration of expo-
sure (Allan et al., 2005). 
These observations give rise to the question whether depression is a neurodegen-
erative disorder that is induced by chronic inflammations. 
 
 
Figure 1: Stress-induced immune activation and the association with neuroendocrine and 
neurotransmitter changes (adapted from (Myint et al., 2007)) 
 
 
1.4 Immune hypothesis of depression 
1.4.1 Psychoneuroimmunology 
 
Psychoneuroimmunology is concerned with the interacion between the nervous, 
endocrine and immune systems. The interfaces are the pi uitary, adrenal glands 
and immune cells. The focus is on the effect of the psyche on the immune system, 
for example how stress can have a negative effect on immune factors. Chronic 
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stress causes a decreased concentration of secretory IgA in saliva and an increased 
release of glucocorticoids. Corticosteroids inhibit cy okine production and reduce 
the reactivity of B and T lymphocytes and the activity of natural killer cells. 
 
 
1.4.2 Basic immunological principles 
 
The cells of the immune system are defined by their surface marker molecules and 
by the cytokines they secrete. CD3 markers are present on all T lymphocytes 
(CD3+). These lymphocytes are divided into several subpopulations, which are 
defined with the help of antibodies and have different functions. They include the 
T helper cells (CD4+), which induce the immune response, and the cytotoxic T 
cells (CD8+), which regulate an existing immune response. They also have toxic 
and lysing effects. Antigen-presenting cells, such as monocytes (the precursor 
cells of macrophages) and certain types of lymphocytes, release activating cyto-
kines, which activate B and T lymphocytes. The T helper 1 system, which consists 
of parts of the cellular system, becomes active in acute inflammations. Cytokines 
characteristic for this process are INFγ, IL-2 and IL-12. These cytokines are pro-
duced not only by T helper cells, but also by monocytes/macrophages and other 
cells. They are referred to as the type 1 immune response. The humoral system, 
called the type 2 immune response, becomes active in chronic inflammation. Pro-
inflammatory cytokines such as TNF-α, IL-1, IL-2 and IL-6 are released mainly 
by monocytes/macrophages (Muller et al., 2007). In small amounts these cyto-
kines cause activation of the adhesion molecules and chemotaxis, with the aim of 
initiating an inflammation and recruiting further leucocytes. If they are present in 
large amounts and if they enter the blood, these cytokines cause the body to react 
with fever, hepatocytes to produce acute phase protein and more leucocytes to be 
released by the bone marrow. TNF-α primarily activates the type 1 immune re-
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sponse, whereas IL-6 activates the type 2 immune response and promotes anti-
body production. The type 1 and 2 immune responses are normally in equilibrium. 
In the CNS, microglial cells and astrocytes are the carriers of the immune re-
sponse. They also release cytokines: microglial cells mainly release type 1 cyto-
kines, astrocytes primarily type 2 cytokines. These two cell types are thus also in a 
functional immunological equilibrium (Aloisi et al., 2000). In recent years studies 
have shown that the proinflammatory and type 1 immune systems are activated in 
depression. 
 
 
1.4.3  Tryptophan metabolism 
 
In the CNS, tryptophan-kynurenine metabolism is mainly localised in microglial 
cells and astrocytes. Proinflammatory cytokines have been found to have a pro-
found effect on the metabolism of serotonin, dopamine and noradrenaline in 
mouse and rats (Dunn et al., 1999). Clinical studies found significantly increased 
tryptophan concentrations in patient serum after administration of IL-2 or IFN-α 
(Brown et al., 1991). The rate-determining step in tryptophan metabolism to 
kynurenine is the activity of the almost ubiquitously expressed enzyme IDO. The 
further conversion of kynurenine to either kynurenic acid or 3-
hydroxykynurenine, the precursor of quinolinic acid, is regulated by the enzymes 
kynurenine aminotransferase and kynurenine hydroxylase. Kynurenic acid is an 
NMDA receptor antagonist, the only endogenous one known so far, and thus in-
teracts with glutamatergic neurotransmission. Quinolinic acid acts as an endoge-
nous NMDA receptor agonist and thus has the opposite effect to kynurenic acid 
on glutamatergic neurotransmission. The activity of IDO and kynurenine hy-
droxylase is regulated by cytokines. Type 1 cytokines such as IFN-γ and TNF-α 
are potent inductors of IDO and kynurenine hydroxylase, while type 2 cytokines 
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such as IL-4 and IL-10 inhibit them (Weiss et al., 1999). Apart from IFN-γ and 
TNF-α, also other mediators of inflammation such as PGE2 induce increased IDO 
activity (Braun et al., 2005, Robinson et al., 2005). The close association between 
the immune system and kynurenine metabolism is reflected in their important 
functions in inflammatory diseases. The degradation of tryptophan to quinolinic 
acid in the CNS can take place in microglial cells and infiltrated mono-
cytes/macrophages but not in astrocytes, because they lack the degrading enzyme 
3-hydroxykynurenine (Saito et al., 1993, Alberati-Giani et al., 1996). In humans, 
the greatest concentrations of quinolinic acid are found in the cortex, not in sub-
cortical regions, which is why it is not surprising that high levels of quinolinic 
acid are associated with disorders of cortical functio s (Heyes et al., 1998). How-
ever, quinolinic acid levels in the blood and CNS are not related to each other: 
during a local inflammatory process in the CNS, quinolinic acid production in-
creases in the CNS but the blood levels remain unchanged. However, an immune 
activation in the blood can result in an increase of quinolinic acid levels in the 
CNS (Saito et al., 1993). Tryptophan availability is the limiting factor in serotonin 
synthesis. A type-1−induced (e.g. IFN-γ), IDO-mediated decrease in the availabil-
ity of tryptophan in the CNS results in a serotonergic deficit (Grohmann et al., 
2003). A positron emission tomography study in depressive patients accordingly 
found a lack of tryptophan in the limbic and paralimb c cortex (Leyton et al., 
2006, Rosa-Neto et al., 2004). In 2003, the possible role of the imbalance between 
neurotoxic and neuroprotective tryptophan metabolites was proposed as a patho-
physiological link between immune activation and neurochemical changes which 
leads to chronic psychiatric disorders such as depression (Myint et al., 2003). 
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Figure 2: Tryptophan-metabolism (adapted from (Myint et al., 2007)) 
 19
1.4.3 Kynurenine metabolites and cytokines as possible biomarkers in 
depression 
 
The term “biomarker” was first introduced in 1989 and defined as a “substance 
used as an indicator of a biologic state”(Zhang et al., 2009). A biomarker can be 
the concentration of a certain enzyme or hormone, th  presence or absence of a 
specific biological molecule or a particular genotype that is only present in a 
population displaying a certain phenotype or endophenotype. Different types of 
biomarkers exist, providing different information. They either allow an objective 
assessment of physiological states and their underlying pathogenesis or give in-
formation about response to pharmacological treatment. Some markers predict 
risk or monitor clinical progress, although they are not causally related to the 
pathophysiology (Zhang et al., 2009). 
Biomarkers can be very useful tools in psychiatry. As mentioned above, one of the 
key goals in psychiatry is to identify possible aetiological factors for disorders  
(Keshavan et al., 2008). However, biomarkers also have great advantages in the 
clinical setting. So far, a diagnosis of depression is made only on the basis of 
clinical features. There is clearly no biological diagnostic test able to supersede a 
clinical diagnosis based on symptoms, but biomarkers can be very useful in moni-
toring and predicting treatment response, compliance, better distinguishing be-
tween subtypes and providing an additional objectiv diagnostic tool. 
Only very recently has evidence accumulated indicating a strong reciprocal con-
nection between the neuronal and immune system. Both appear to communicate 
via neurotransmitters and cytokines and can even regulate each other (Petrovsky, 
2001, Masek et al., 2003, Reyes-Garcia et al., 2009). Cytokines are small proteins 
that regulate infection in inflammation (Kronfol et al., 2000). Cytokines thus rep-
resent possible immunological peripheral markers of physiological states in the 
brain. Cytokines from the periphery could either enter the brain directly and affect 
neurons, astrocytes and microglia (Quan, 2008, Monji et al., 2009, Watanabe et 
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al., 2010) or activate and modulate certain metabolic pathways whose metabolites 
have harmful effects on the neuronal system. The kynurenine pathway is one of 
the pathways that have been consistently correlated with major psychiatric disor-
ders (Myint et al., 2007a, Myint et al., 2007b, Kim et al., 2009). The studies by 
Myint and co-workers suggested that tryptophan breakdown and kynurenine me-
tabolites play a role in all three major psychiatric d sorders, namely major depres-
sion, bipolar disorder and schizophrenia. Although these disorders have different 
clinical symptoms, the changes in the interaction between the immune system and 
the tryptophan pathway show some similarities. Kynure ine metabolites and cer-
tain cytokines could thus serve as biomarkers, since specific metabolic and immu-
nological changes might only appear in depression. 
 
 
1.5 Drugs for the treatment of depression 
1.5.1 Antidepressants 
 
Antidepressants are a heterogeneous group of active substances that treat depres-
sive disorders of different causes and with different characteristics by improving 
mood or increasing drive, or both. They act across di ease classifications, i.e. in 
depressive disorders of different causes. Clinical studies show that antidepressants 
are effective in the acute treatment of depressive d sorders of all severities. Their 
efficacy is mainly based on their effects on one or m e neurotransmitter systems 
(serotonin, noradrenaline, dopamine) in the CNS. Many ntidepressants also af-
fect other neurotransmitter systems (e.g. acetylcholinergic or histamniergic), 
which can result in side effects. Treatment with antidepressants is divided into 
acute treatment, maintenance treatment for up to 12 months and relapse prophy-
laxis that can last years. 
The best known antidepressants can be separated into the following groups: 
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- Tricyclic antidepressants 
 
The tricyclic antidepressants were the most frequently prescribed until the advent 
of the serotonin reuptake inhibitors. One of their main disadvantages is the rela-
tively long latency of antidepressant effect of 4 to 6 weeks. All tricyclic antide-
pressants inhibit to varying degrees the reuptake of serotonin and noradrenaline 
from the synaptic cleft. Furthermore, depending on the type of binding they act as 
antagonists of different strengths at central receptors. These receptors include his-
taminergic, muscarinergic, alpha-adrenergic, dopaminergic and serotonergic re-
ceptors. The effects at these receptors determine the side-effect profile of the dif-
ferent substances, which is relevant for treatment. 
The tricyclics are divided into two main classes: trtiary amines (e.g. imipramine), 
which act as dual reuptake inhibitors, are metabolised to secondary amines and 
have particularly pronounced anticholinergic side eff cts; and secondary amines 
(e.g. desipramine), which inhibit noradrenaline reuptake somewhat more selec-
tively and have fewer anticholinergic effects. These vegetative side effects are 
noticeable mainly in the regulation of blood pressure, the digestive system, car-
diac rhythm and in the sleep-wake cycle. 
 
- Selective serotonin reuptake inhibitors 
 
These days, selective serotonin reuptake inhibitors (SSRIs) are the most com-
monly used drugs in depression. In up to 50% of patients they take effect already 
after 2 to 3 weeks. SSRIs selectively inhibit the reuptake pump for serotonin at the 
synaptic cleft and thus increase the “relative” concentration of the transmitter. 
Serotonin can thus bind more to all 5-HT receptor subtypes. The 5-HTA autore-
ceptors and presynaptic 5-HT1B/D receptors, which have a control function via a 
negative feedback mechanism, are also more strongly activated. The continual 
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stimulation of these receptors results in their destabilisation and down-regulation, 
which shows a very close temporal correlation with the delayed onset of the anti-
depressive effect. 
The family of SSRIs includes fluoxetine, fluvoxamine, paroxetine, citalopram, 
escitalopram and sertraline. They are characterised by a generally mild side-effect 
profile, but frequent sexual dysfunctions, strong hepatic metabolization and rela-
tively low affinity for histaminergic, dopaminergic, alpha-adrenergic and cho-
linergic receptors. They alter REM sleep and are saf r than tricyclics in case of 
overdose. 
 
- Selective noradrenaline reuptake inhibitors 
 
Reboxetine is the only selective noradrenaline reuptake inhibitor (SNRI). The 
reuptake of noradrenaline from the synaptic cleft rsults in a down-regulation of 
α2 and β receptors and in an increased sensitivity of post-synaptic α1 receptors. 
The main side effects are sympathetic vegetative eff cts such as tachycardia, 
tremor and sweating, but also problems with micturation. 
 
- Selective serotonin-noradrenaline reuptake inhibitors 
 
Like tricyclics, selective serotonin-noradrenaline reuptake inhibitors (SSNRIs) 
affect the reuptake of both serotonin and noradrenaline. However, they do not 
block any monoaminergic receptors. Venlafaxine is the only drug of this class 
currently on the market in Germany. 
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- Monoamine oxidase inhibitors 
 
Monoamine oxidase inhibitors (MAO inhibitors) act by locking the enzyme 
monoamine oxidase. This enzyme cleaves amines such as serotonin and 
noradrenaline, i.e. transmitters in the synaptic cleft, and thus decreases their avail-
ability for transmitting signals in the CNS. Thus, blocking the enzyme results in a 
“relative” increase of the neurotransmitters in the synaptic cleft. MAO-A metabo-
lises dopamine and phenylethylamine and MAO-B degrades serotonin and 
noradrenaline. 
MAO inhibitors are divided into selective and non-selective MAO inhibitors. Se-
lective reversible inhibitors of MAO-A (e.g. moclobemide) inhibit only type A 
monoamine oxidase; MAO-B−inhibiting active substances (e.g. selegiline) are 
primarily used to treat Parkinson’s. Non-selective, irreversible MAO inhibitors 
(e.g. isocarboxazid, tranylcypromine) inhibit MAO-A and MAO-B. 
 
 
1.5.2 Immune effects of antidepressants 
 
Some antidepressants seem to shift the balance between the type1 and type2 im-
mune response from a proinflammatory to an anti-inflammatory immune re-
sponse. An in vitro study showed that substances such as sertraline, clomipramine 
or trazodone significantly reduce the ratio of INF-γ to IL-10 (i.e. the ratio between 
pro- and anti-inflammatory cytokines). These antidepressants reduce the produc-
tion of INF-γ. Sertraline and clomipramine, on the other hand, cause a significant 
increase in IL-10 (Maes et al., 1999). The relevance of cytokines for the patho-
genesis of depressive disorders is also confirmed by the fact that when hepatitis C 
or malignant melanoma are treated with INF-γ, a large proportion of patients de-
velop a depression requiring treatment. Studies have shown a decrease in proin-
flammatory cytokines after treatment of major depression (MD). This is not a sec-
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ondary effect but a direct effect of antidepressant o  the immune cells. The exact 
mechanism has yet to be determined. However, the fact th t 5-HT1 and 5-HT2 
receptors as well as high affinity 5-HT transporters have been demonstrated on the 
cells suggests involvement of the serotonergic system. This process is supported 
by the anti-inflammatory and peripherally analgesic effects of 5-HT2 antagonists 
(Sasaki et al., 2006). Serotonin antagonist and reuptake inhibitors (SARI) such as 
trazodone also have this mode of action, which could explain their good efficacy 
in treating exacerbations of pain in depression, fibromyalgia and somatoform dis-
orders. In vitro studies also suggest that, by binding to the 5-HT2C receptor, tra-
zodone also indirectly inhibits an increase of the second messenger cGMP caused 
by agonists at the NMDA receptor (Marcoli et al., 1998). Trazodone may also 
have neuroprotective effects through the inhibition of the glutamatergic effects at 
the second messenger level. 
 
 
1.5.3 New treatment approach: COX-2 inhibitors as antidepressants 
 
Prostaglandin E2 (PGE2) is an important mediator of inflammation. Signs of in-
flammation, increased proinflammatory cytokines and increased level of PGE2 
have been described in MD. An in vitro study reports higher PGE2 secretion from 
lymphocytes of depressed patients than from those of healthy controls (Song et 
al., 1998). Also, some animal studies show that COX-2 inhibition can lower the 
increase of proinflammatory cytokines such as IL-1β, TNF-α and PGE2 and can 
also decrease clinical symptoms like anxiety and clinical decline.  Because of the 
involvement of PGE2 in the pathophysiology of MD, Müller and coworkers per-
formed a clinical trial using the COX-2 inhibitor celecoxib: the group of patients 
treated with reboxetine alone showed a 49% improvement of symptoms. In addi-
tion to this therapeutic effect, the data clearly showed an advantage and trend to-
wards significance of the combination of reboxetine a d celecoxib (Muller et al., 
 25
2006). The clinical antidepressant effect of COX-2 inhibitors can be explained by 
their anti-inflammatory effects in the CNS. Treatment with a COX-2 inhibitor 
prevents the dysregulation of the HPA axis and the increase of cortisol, which has 
a key function in MD (Hu et al., 2005). In an animal odel the functional effect of 
IL-1 (e.g. sickness behaviour) and other proinflammatory cytokines in the CNS 
were found to be antagonized by treatment with a selective COX-2 inhibitor (Cao 
et al., 1999). A possible antidepressant effect of he COX-2 inhibitor rofecoxib 
has already been observed in osteoarthritis patients with comorbid depression 
(Collantes-Estevez et al., 2003).  
 
 
1.6 Aim of the Study 
 
The aim of this case-control study was to evaluate the in vitro effects of certain 
psychopharmaceutical drugs such as reboxetine, venlafaxine, fluoxetine, 
imipramine and celecoxib on peripheral monocytes and their kynurenine metabo-
lism and cytokine release. Also, the effect of the mitogen LPS on kynurenine me-
tabolism and cytokine release was investigated. Our hypothesis was that inflam-
matory processes give rise to greater concentrations of the products of this 
metabolism in the body and that these influence processes in the brain, so that 
they may be valid biomarkers for depression. Whole blood cultures from depres-
sive patients were compared with those of healthy, age-matched controls. The pro- 
and anti-inflammatory cytokines were measured with the ELISA analysis tech-
nique and the results with and without medication cmpared. At the same time, 
the concentrations of the tryptophan metabolites formed with and without psycho-
pharmaceuticals were measured by means of high pressure liquid chromatography 
(HPLC). 
 26
2 Material and Methods  
 
21 patients (9 male and 12 female) displaying major depression were recruited 
from the psychiatric hospital of the Ludwig Maximilians University (LMU) in 
Munich. Psychiatric diagnosis was confirmed via clini al interview using DSM-
IV criteria. The inclusion criteria also include age between 18-60 years and both 
gender. Exclusion criteria included acute and chronic infections, chronic inflam-
matory and autoimmune diseases and anti-inflammatory and immunosuppressive 
medication. 5 of the patients were “drug-free” patien s who did not take any 
antidepressive medication. The remaining 16 patients took different drugs, includ-
ing levothyroxine sodium, glimepiride, enalapril, escitalopram, seratraline, 
zopiclone, lorazepam, paroxetine, thyroxine, amitryptiline, citalopram, levothy-
roxine sodium and potassium iodide, mirtazapine, venlafaxine and  bupropion.  
History of smoking and drug and alcohol use and other medications were record-
ed. 38 control persons were matched for age and gener and exclusion criteria are 
the same as in depressive patients. For both, patients and controls, the same pro-
cedure, consisting of questionnaires and blood colle tion, was applied. Except for 
HAMD and MRDS interview, this was only done in patients. The study was ap-
proved by the responsible Institutional Ethical Committee of the LMU, and all 
patients and controls provided written, informed consent. 
 
 
2.1 Psychological Parameter 
 
Personal data of all patients and controls were colle ted with a short anamnesis. 
All possible confounding factors, such as weight, heig t, smoking, drug- or alco-
hol abusus, acute infection diseases and medication were documented.  
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For the psychological data following interviews were arranged: 
- The M.I.N.I is a short and structured interview fordiagnosting psychi-
atric diseases in DSM-IV and ICD-10.  It was develop d for not pro-
fessional interviewers. The interview takes about 15 min, consists of 
17 modules and each of them contains one diagnostic cri eria.  The 
questions should be answered only with yes or no. Studies have shown 
that the reliability and validity according to the CIDI were really high 
but can be arranged in a shorter term (Amorim et al., 1998). 
 
- The Perceived Stress Scale (PSS) is one of the most frequently used 
psychiological instruments for measuring the perception of stress with 
a five point Lickert Scale. Response alternatives are: 1. Never, 2. Al-
most never, 3. Sometimes, 4. Fairly often, 5. Very often. Its main pur-
pose is to provide a measurement to which degree certain situations in 
one`s life are perceived as particular stressful. Items comprise ques-
tions about their lives. It also includes queries about the current level of 
experienced stress. The items are easy to understand and the response 
alternatives are simple to grasp (Cohen et al., 1983). There are three 
different kinds of the scale, either consisting of four (PSS-4), ten (PSS-
10) or fourteen (PSS-14) items. In this study, the PSS-14 was used. 
 
- The Life event questionnaire is an inventory-type questionnaire in 
which subjects mark the life events or changes which ave occurred 
during the past year. It indicate whether the event was considered 
“good” or “bad” and rates the impact of the event o a 4-point scale. 
 
- The attitude towards life was screened with an interview of eight ques-
tions which are related to the daily routine. The possibilities for an-
swering were “yes”, “no” or “unclear”.  
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- The Hamilton Depression Scale (HAMD) is a depression test measur-
ing the severity of depression symptoms. The scale is basically quanti-
tative. It was constructed for the sole purpose of rating the actual clini-
cal picture, and it is not to be considered a diagnostic tool (Hamilton, 
1960). 
 
- The Montgomery-Asberg Depression Rating Scale (MADRS) is a 10-
item diagnostic questionnaire which is used to measure the severity of 
depressive episodes in patients with disorders.  
 
 
2.2 Biochemical parameters 
 
8 x 5.5 ml of venous blood were withdrawn with a heparinised blood tube (Sigma) 
between 8-10 am. During a period of 1-2 hours two identical Cell Star 24-well 
plates (Greiner Bio One) were prepared with stimulant and antidepressants. Pe-
ripheral blood was added. After 72 hours of incubation at 37° C, 600µl of super-
natant was removed. Cytokines were determined by Millipore`s MILLIPLEX map 
High Sensitivity Human Cytokine Panel (Millipore Corp ration, Billerica, MA). 
For the different concentrations of kynurenine metabolites Ultra Performance 
Liquid Chromatography and Mass Spectrometry (UPLC-MS/ S) method was 
used. 
 
 
2.2.1 Study design 
 
Each well of the Cell Star 24 well plate contained a total volume of 1ml which 
was composed out of different antidepressants, RPMI medium with stimulant 
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(750 µl when no antidepressant was added) and whole bl od (250µl). Lipopoly-
saccharide (LPS) (from Salmonella; Sigma) was used a  a stimulant. LPS concen-
tration in each well was 4.3 µg/ml. The antidepressants which were used in this 
study, were fluoxetine, reboxetine, venlafaxine, imipramine and celecoxib. Anti-
depressant concentrations in the appropriate wells were 50ng/ml, 200ng/ml, 
250ng/ml, 300 ng/ml and 350ng/ml respectively. Afterwards, the plate was incu-
bated for 72 h at 37 degree in humidified chamber with 5 % CO2. 
 
 
2.2.2 In vitro LPS stimulation 
 
LPS is released from Gram-negative bacteria and is a strong inducer of the innate 
immunity (Bernardi et al., 2009, Wang et al., 2006). It acts through the toll-like 
receptor 4 (TLR-4), amember of the toll-like family that play a central role in the 
recognition of infectious pathogens and are expressed on immune cells, including 
macrophages, dendrites, B and some Tcells (Wang et al., 2006). LPS binds TLR-4 
receptor via an leucine-rich extracellular domain and signaling involves the re-
cruitment of a number of intracellular adaptor protein that activate transcription 
factors and protein kinases that induce production of i flammatory agents (Wang 
et al., 2006). In experimental biology, LPS is used to mimic a bacterial infection. 
 
 
2.3 Sample analysis 
2.3.1 Cytokine concentrations 
 
The supernatant concentrations of IL-4, IL-10, IFNγ and TNF-α were determined 
using Millipore´s MILLIPLEX map High Sensitivity Human Cytokine Panel 
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(Millipore Corporation, Billerica, MA). Detection range was 0,13 pg/ml to 
10000pg/ml. Acquired fluorescence data were analysed using Bio-Plex software 
(version 4.1; Bio-Rad Laboraties). Preparation assay w s performed according to 
the manufacturer`s protocol by using customized reagents and solutions. 
 
 
2.3.1.1 Milliplex TM  map kit principle 
 
Multianalyte profiling for IL-4, IL-10, IFN- γ, TNF- α in whole blood supernatant 
was performed on the Bio-Plex Luminex system (Bio-Rad Laboratories, INC., 
Hercules, California), which is based on the Luminex® x MAP® technology. 
Luminex ® uses probrietary techniques to internally colourcode microspheres with 
two fluorescent dyes. Through precise concentrations of these dyes, 100 distinctly 
colored bead sets can be created. Each of which is oated with a specific capture 
antibody. After an analyte from a test sample is captured by the bead, a 
biotinylated detection antibody is introduced. The reaction mixture is then incu-
bated with Streptavidin-PE conjugate, the reporter molecule, to complete the reac-
tion on the surface of each microsphere. The microspheres are allowed to pass 
rapidly through a laser which excites the internal dyes marking the microsphere 
set. A second laser excites PE, the fluorescent dye on the reporter molecule. Final-
ly, high-speed digital-signal processors identify each individual microsphere and 
quantify the result of its bioassay based on fluorescent reporter signal. This capa-
bility  of adding multiple conjugated beads to each sample results in the ability to 
obtain multiple results from each sample. Open-archite ture x MAP r technology 
enables multiplexing of many types of bioassays reducing time, labor and costs 
over traditional methods. This Bio-Plex suspension arry system is a flow-based 
dual-laser system for simultaneously identifying and quantitating up to 100 differ-
ent analytes in a single biomolecular assay. 
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Reagents supplied by the kit: Materials required but not provided: 
 High Sensitivity Human Cytokine 
Standard 
 High Sensitivity Human Cytokine 
Quality Controls 1 and 2 
 Set of one 96- Well Filter Plate with 2 
Sealers 
 Assay Buffer 
 10x Wash Buffer 
 High Sensitivity Human Cytokine 
Detection Antibodies 
 Streptavidin- Phycoerythrin 
 Mixing bottle 
 Premixed 13 plex Beads for IL-10,  
 IL-4, IFNγ, TNFα 
 
 Luminex Sheath Fluid 
 Adjustable pipets with Tips capable of 
delivering 25 µl to 200µl 
 Multichannel Pipets capable of deliver-
ing 5 µl to 50µl 
 Reagent reservoirs 
 Polypropylene Microfuge Tubes 
 Rubber Bands 
 Absorbent Pads 
 Laboratory Vortex Mixer 
 Sonicator 
 Titer Plate Shaker 
 Vacuum Filtration Unit 
 Luminex 100 tm IS, 200 tm or HTS by 
Luminex Corporation 
 Plate Stand 
 
Table 1: Reagents and materials for cytokine analysing 
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2.3.1.2 Preparation of reagents 
 
Quality Controls 
Before use, Quality Control 1 and Quality Control 2 were reconstituted with 250 
µl deionized water. The vial was inverted several times to mix and let rest for 5-10 
minutes. 
 
High Sensitivity Human Cytokine Standard 
Prior to use, High Sensitivity Human Cytokines Stand rd was reconstituted with 
100 µl deionized water to give a 10000 pg/ml concentration of standard for all 
analytes. The vial was inverted several times to mix and vortexed for 10 seconds. 
Then it was let rest for 5-10 minutes. 
 
Working Standards 
The standard working solution ranged from 0.13 to 10000pg/ml. 130 µl of deion-
ized water was added to one tube and 200 µl of assay buffer to six other tubes. 30 
µl of the 10000pg/ml was added to the first tube with the deionized water, to get 
2000 pg/ml concentration. Then 50µl of the 2000 pg/ml is transferred to the next 
tube to create 400pg/ml concentration. Always 50 µl of the former dilution is add-
ed to the next tube. This gave the concentrations of 80 µl, 16µl, 3.2µl, 0.64µl and 
0.13µl, respectively. The 0 pg/ml standard (Background) was Assy Buffer. 
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2.3.1.3 Immunoassay procedure 
 
The filter plate was pre-wet by adding 200µl wash buffer to each well. Then it 
was sealed and shook on plate shaker for 10 minutes at room temperature. Wash-
ing buffer was removed by vacuum and 25µl of premixd beads were added to 
each well. The fluid was removed by vacuum again. 50µl of standard or control 
were added in the appropriate wells. 50µl of assay buffer was added to the back-
ground and sample wells and 50 µl of RPMI medium was added to the control and 
standard wells. Then after centrifuging the samples, 50 µl of each was added to 
the appropriate wells. The plate was incubated for 17 hours at 4°C with shaking. 
After 17 hours, the fluid was gently removed by vacuum and the plate was washed 
twice by vacuum filtration between each wash. Subsequently 50µl of Streptavi-
din-Phycoerythrin was added to each plate and incubated again for 30 minutes at 
room-temperature for 30 minutes. In the next step, all contents were removed by 
vacuum and washed twice with 200µl washing buffer with vacuum filtration be-
tween each wash. In the last step, 100µl of Sheath Fluid was added to all wells 
and shaked for 5 minutes to suspend beads. The plat was run on Luminex 100 
Tm and acquired fluorescence data were analysed using Bio-Plex software (ver-
sion 4.1; Bio-Rad Laboraties). 
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2.3.2 Tryptophan and Kynurenine concentration 
2.3.2.1 Solid-phase extraction 
 
Solutions Ingredients 
Internal standard 7.5 µl N-TYR stock solution (1mg/l) dissolved in 1 ml 
9 M H3PO4 (phosphoric acid) 
Equilibration fluid 1  Methanol 
Equilibration fluid 2 H2O 
Washing solution 0.1 M citric acid 
Elution fluid 
 
200 ml MTBE (ter-butyl methylether) with 400 ml 
acetonitril and 5% NH4OH (Ammoniumhydroxid) 
Table 2: Solutions for solid-phase extraction 
 
Extraction: 
For the equilibration process equilibration fluid 1 and equilibration fluid 2 is add-
ed to the solid-phase column (Oasis MCX 1cc) and carefully sucked dry. After-
wards sample is added together with 50µl of internal st ndard and mixed well. 
The column is washed subsequently in 1ml washing solution, dried and centri-
fuged for 5 minutes. Then, the sample is eluted in the elution fluid and evaporated 
for 15-30 min with nitrogen at 40°. In the following sample is taken up in 100 µl 
H2O (MS method: KYN 2350) and this solution is again d luted 1:100 (MS meth-
od: KYN 1350). Of both solutions 10µl are injected using the full loop option. 
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2.3.2.2 Chromatographic system and conditions 
 
The analysis was carried out on a Water AQUITY UPLC (TM) system with cool-
ing autosampler and column oven. An ACQUITY UPLC tmHSST3 column 
(50mm x 150 mm, 1.8 µm (Waters Corp, Milford, MA, USA)) was employed for 
separation with the column temperature maintained at 45°C. The gradient elution 
for UPLC analysis consisted of two solvent compositi ns: Solvent A 0.1% acetic 
acid in water and solvent B 0.1% acetic acid in methanol. The gradient began with 
98% eluent A and changed linearly to 50 % A within 10 min, goes to 100% meth-
anol in 20min, stayed for 2 min and changed back to 98 % A withon 2 min and 
stayed 5 min. Throughout the UPLC process the flow rate was set at 0.35 ml/min 
and the run time was 21 min. A Waters Xevotm tandem quadropole mass spec-
trometer (Waters Corp., Milford, MA, USA) equipped with an electrospray ioni-
zation (ESI) interface was used for analytical detection. The ESI source was set in 
positive ionization mode. Quantification was performed using MRM of the transi-
tions of M7Z 209.1 to 94.1 for kynurenine and m/z 205.1 to 146.1 tryptophan, 
with scan time of 0.025 per transition. The optimal MS parameters were as fol-
lows: capillary voltage 3.5 kV, cone voltage 8 V, source temperature 150°C and 
desolvation temperature 600°C. Nitrogen was used as the desolvation and cone 
gas with a flow rate of 800 and 4 L/h, respectively. Argon was used as the colli-
sion gas at a pressure of approximately 0.3 Pa. The optimized collision energy for 
kynurenine was 20 V and for tryptophan 22 V. All data collected in multi-channel 
analysis (MCA) mode were acquired and processed using Mass Lynx tm V 4.1 
software with Target Lynx tm V 4.1 program (Waters Corp., Milford, MA, USA).  
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2.4 Statistical analysis 
 
The Kolmogorov-Smirnov test was used to check the normality of the data in pa-
tients and control groups. Descriptive statistics toge her with plots (error bars cor-
respond to 95% confidence intervals) were provided. To compare skewed data 
between groups a non-parametrical test Mann Whitney U test was applied. For 
normally-distributed data, the two sample Student´s t- est was applied. To control 
for the different confounding factors multiple univariate analysis was used. These 
tests were made with SPSS 18.0 (SPSS Inc., Chicago, Illin is).  
The null hypothesis was rejected at P < 0.05. For faster illustration in the graphs, 
the following categories for P-values were used: < 0.001 = ***, from 0.001 until 
0.01 =**, from 0.01 until 0.05 =* and from 0.05 until 0.1 = # (tendency).  
For the summary, statistical results were summarized n an Excel spreadsheet 
(Microsoft Office) and the mean values were integrated as a graphical presenta-
tion in the text. 
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3 Results 
3.1 Demographic data 
 
Altogether we included 59 Caucasian study participants - 21 patients suffering 
from depression and 38 healthy control individuals – who fulfilled the inclusion 
criteria as described in chapter 2 “Material and Methods”. Several psychopatho-
logical scores like PSS, life event - and attitude towards life questionnaire, 
M.I.N.I, HAMD and MADRS were carried out. The median ge for patients was 
43.19 and for healthy controls 45.61. The percentage of men was similar in the 
patient group (75%) and in the control group (73%), so the male:female ratio did 
not differ significantly between the two groups . The same was true for body mass 
index (BMI; p = 0.460) and the age (p = 0.201). The parameters medication (p = 
0.356), nicotine abusus (p = 0.754) and race (p = 1.0) showed no difference be-
tween the groups. A significantly higher number of patients than healthy controls 
had a history of alcohol consumption (p = 0.04) and family history of depression 
(p< 0.001). Concerning the medication status, only five patients did not receive 
any medication before the diagnosis MD was confirmed. So only these people 
were drug naïve with a recent onset of MD. 
 
Tabel 3 is presenting the epidemiological and clinial data of the 59 participants 
who were included into our study (Tab.3). 
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Patients with major de-
pression (n=21) Healthy controls (n=38) 
   
Sex (male/female) 9/12 16/22 
Age (years) 43.19 45.61 
BMI (kg/m2) 24.14 25.58 
Family History (yes/no) 8/13 0/38 
Alcohol 4/17 0/38 
Drug 1/21 0/38 
Nicotine 4/21 9/38 
   
Antidepressant medication 
status   
Medication-free 5/21  
Psychopathology scores:   
PSS 45.57 42.18 
Life Events   
Attitude towards life 54.07 42.18 
HAMD 13.93  
MADRS 18.86  
Table 3: Demographic data of study participants 
 
 
3.2 Immunological findings: cytokines 
 
Whole blood cultures were stimulated with LPS and different antidepressant med-
ications were added. After incubation for 72 h, the supernatant was removed. The 
concentrations of the cytokines IFN-γ, IL-4 and IL-10 were determined by Milli-
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pore´s MILLIPLEX map High Sensitivity Human Cytokine Panel. IFN-γ levels, 
which characterize the Th1 immune response, and IL-4 and Il-10, which represent 
the Th2 immune response are presented separately below. 
 
 
3.2.1 Th1/proinflammatory cytokines: IFN- γ 
 
 
Figure 3: Mean in vitro IFNγ concentrations (pg/ml) in whole blood cultures from patients 
with major depression and healthy controls after incubation of cultures under different con-
ditions. Bars (Control, Depression) show the concentrations in the two study groups, error 
bars correspond to 95% confidence intervals, and ´#` indicates a p-value in the range 0.05 to 
0.1 (exceptionally Mann-Whitney U test was used her).   
 
The mean IFN-γ production before and after LPS stimulation was compared be-
tween patients and controls. The controls` mean values were numerically higher 
across the different culture conditions, however, none of the differences was sta-
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tistically significant, although the culture condition treated with LPS and ven-
lafaxine showed a trend towards statistical difference (p = 0.071; Mann-Whitney 
U test) (Fig. 3).  
In the culture from healthy controls, which contained celecoxib as a antiinflamma-
tory drug, the mean value of the IFN-γ concentration reached the lowest level 
compared to other medications after LPS stimultation. This numerical decline of 
IFN-γ was only detectable in the blood from healthy controls but not in the blood 
from patients. 
Group also had no effect (either depressed or control) on the level of IFN-γ when 
the parameters family history and alcohol were controlled in a univariate analysis 
of variance. 
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3.2.2 Th2/antiinflammatory cytokines: IL-4, IL-10 
 
 
Figure 4: Mean in vitro IL4 concentrations (pg/ml) in whole blood cultures from patients 
with major depression and healthy controls after incubation of cultures under different con-
ditions. Bars (Control, Depression) show the concentrations in the two study groups and 
error bars correspond to 95% confidence intervals. 
 
After incubation under different conditions, no significant differences were found 
between IL-4 levels in the depressed and control grups, although the absolute 
values increased (Fig.4). However, in a univariate analysis of variance, alcohol 
consumption showed an effect on IL-4 when blood cultures were stimulated with 
LPS (p< 0.001), and treated with fluoxetine (p = 0.048), reboxetine (p = 0.005), 
venlafaxine (p = 0.002) or imipramine (p = 0.015), but not with celecoxib. 
Celecoxib had no significant effect on IL-4 production. Family history also corre-
lated significantly with the IL-4 level after treatment with LPS and reboxetine (p 
= 0.008). 
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Figure 5: Mean in vitro IL10 concentrations (pg/ml) in whole blood cultures from patients 
with major depression and healthy controls after incubation of cultures under different con-
ditions. Bars (Control, Depression) show the concentrations in the two study groups, error 
bars correspond to 95% confidence intervals, ´*` indicates a p-value in the range 0.01 to 0.05 
(exceptionally Mann-Whitney U test was used here)  and ´***`indicates a p-value < 0.001. 
 
The mean IL-10 values of the control group were higher than those of the patient 
group across all conditions. However, the differences only reached statistical sig-
nificance in the unstimulated culture (p = 0.039; Mann-Whitney U test). Signifi-
cant differences were observed for the cultures with LPS and fluoxetine (p< 
0.001), reboxetine (p< 0.001) and venlafaxine (p< 0.001). The significant differ-
ence between both groups was abolished in the cultures which were treated with 
LPS and imipramine or celecoxib mainly due to a numerical increase of the IL-10 
concentration in the patient group (Fig.5).  
Group (either depressed or control) had no effect on he level of IL-10 when the 
parameters family history and alcohol were controlled in a univariate analysis of 
variance. 
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3.3 Metabolites of the Tryptophan pathway 
 
One of the main questions was the effect of antidepressant drugs and celecoxib on 
the kynurenine pathway. This section presents the concentrations and ratios of the 
TRP catabolites in the order of the biochemical pathw y. The mean concentra-
tions are presented and compared and the influence of onfounding factors like 
family history, alcohol consumption and diagnosis are controlled.  
 
 
3.3.1 Metabolites 
 
 
Figure 6: Mean in vitro TRP concentrations (µg/ml) in whole blood cultures from patients 
with major depression and healthy controls after incubation of cultures under different con-
ditions. Bars (Control, Depression) show the concentrations in the two study groups and 
error bars correspond to 95% confidence intervals.  
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Stimulation with LPS induced a reduction in TRP levels. Remarkably, in every 
condition mean TRP concentration, after adding LPS, were higher in patients than 
in controls (Fig.6). However, the differences did not reach statistical significance 
in any of the conditions in either the t-test or when confounding factors were con-
sidered in a univariate analysis of variance. 
 
 
Figure 7: Mean in vitro KYN concentrations (ng/ml) in whole blood cultures from patients 
with major depression and healthy controls after incubation of cultures under different con-
ditions. Bars (Control, Depression) show the concentrations in the two  study groups, error 
bars correspond to 95% confidence intervals and ´#` indicates a p-value in the range 0.05 to 
0.1. 
 
The means of KYN concentrations were numerically higher in controls than in 
patients. However, the differences were not significant and only the difference in 
the culture treated with LPS and reboxetine showed a trend towards statistical 
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difference (p = 0.084) (Fig.7). When tested for confou ding factors in a univariate 
analysis of variance, no significant differences were observed. 
 
 
 
Figure 8: Mean in vitro OHK concentrations (ng/ml) in whole blood cultures from patients 
with major depression and healthy controls after incubation of cultures under different con-
ditions. Bars (Control, Depression) show the concentrations in the two  study groups and 
error bars correspond to 95% confidence intervals. 
 
In every condition, the mean OHK concentrations were slightly higher in the de-
pressed group than in the controls; however, none of the differences was signifi-
cant (Fig.8). Also, a univariate analysis of variance showed no statistically signifi-
cant findings related to alcohol consumption or family history. 
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Figure 9: Mean in vitro HAA concentrations (ng/ml) in whole blood cultures from patients 
with major depression and healthy controls after incubation of cultures under different con-
ditions. Bars (Control, Depression) show the concentrations in the two  study groups and 
error bars correspond to 95% confidence intervals. 
 
AA showed no significant differences in the mean cocentration between the two 
groups. However, it is noteworthy that HAA is the only parameter in the catabolic 
pathway of TRP, that decreased after LPS induction (Fig.9). A univariate analysis 
of variance showed no statistically significant findi gs relating to alcohol con-
sumption or family history. 
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Figure 10: Mean in vitro KYNA concentrations (ng/ml) in whole blood cultures from pa-
tients with major depression and healthy controls after incubation of cultures under differ-
ent conditions. Bars (Control, Depression) show the concentrations in the two  study groups, 
error bars correspond to 95% confidence intervals and ´#` indicates a p-value in the range 
0.05 to 0.1. 
 
The mean concentrations of the neuroprotective metaboli e KYNA increased after 
LPS stimulation in both groups as assumed. Values wre higher in the control 
group than in the patient group, but differences were not significant. Only the 
stimulation with LPS showed a trend towards a plunted increase in patients (p = 
0.084) (Fig.10). The addition of medications did not result in a difference between 
patients and controls. 
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Figure 11: Mean in vitro AA concentrations (ng/ml) in whole blood cultures from patients 
with major depression and healthy controls after incubation of cultures under different con-
ditions. Bars (Control, Depression) show the concentrations in the two  study groups and 
error bars correspond to 95% confidence intervals. 
 
In vitro production of the metabolite AA increased with LPS stimulation and was 
higher in the control group than in the patients group across all culture conditions 
(Fig.11). However, differences were not significant i  either the t-test or when 
influencing parameters were considered in a univariate analysis of variance. 
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3.3.2 Ratios between the metabolites 
 
For analysing biochemical pathways, it is important to investigate not only the 
levels of the single intermediates but also to focus on the ratios between the me-
tabolites. Out of that we can get informations about the conversion rates of the 
distinct enzymatic steps. Before going into details, it can be summarized that near-
ly all ratios, except OHK/KYN, were higher in controls than in patients.  
 
 
Figure 12: Ratio of mean concentrations of KYN/TRP in whole blood cultures from patients 
with major depression and healthy controls after incubation of cultures under different con-
ditions. Bars (Control, Depression) show the concentrations in the two study groups and 
error bars correspond to 95% confidence intervals. 
 
The ratio of KYN/TRP describes the first enzymatic step in the degradation path-
way and is referred to as the “tryptophan breakdown index”. It is calculated by: 
kynurenin/tryptophan. The index indicates indirectly the sum of activities of TDO 
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and IDO. Generally, the ratios of different conditions were numerically higher in 
the control group, but none of the differences betwe n groups was significant 
(Fig.12).  
 
 
 
Figure 13: Ratio of mean concentrations of KYNA/KYN in whole blood cultures from pa-
tients with major depression and healthy controls after incubation of cultures under differ-
ent conditions. Bars (Control, Depression) show the concentrations in the two study groups, 
error bars correspond to 95% confidence intervals and ´*` indicates a p-value in the range 
0.01 to 0.05. 
 
The ratio KYNA/KYN allows a statement to be made regarding the 
neuroprotective and neurodegenerative distribution of the metabolites, because 
both KYNA and QUIN are formed from KYN. Therefore, this ratio is also called 
as the “neuroprotective ratio”. In the unstimulated condition, the ratio was signifi-
cantly higher (p = 0.045) in the controls than in the patients. This difference was 
no longer present when the blood was stimulated. Generally, the ratio decreased 
after stimulating the whole blood cultures (Fig.13)  
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Figure 14: Ratio of mean concentrations of OHK/KYN in whole blood cultures from patients 
with major depression and healthy controls after incubation of cultures under different con-
ditions. Bars (Control, Depression) show the concentrations in the two study groups, error 
bars correspond to 95% confidence intervals and ´*` indicates a p-value in the range 0.01 to 
0.05. 
 
The OHK/KYN ratio decreased in both patients and controls after treatment with 
LPS alone or with antidepressant drugs. This part of the catabolism represents the 
first step towards the neurodegenerative metabolite QUIN. In the unstimulated 
condition, the mean ratio of OHK to KYN was higher in controls than in patients, 
but this relation was reversed after stimulation, i.e. t was higher in the patient 
group than in the control group. The mean OHK/KYN ratio was significantly 
higher in the patient group than in the control group in stimulated cultures treated 
with fluoxetine (p = 0.033), reboxetine (p = 0.03) and celecoxib (p = 0.03) alt-
hough there were no significant differences in the individual metabolites OHK 
and KYN (Fig.14). 
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Figure 15: Ratio of mean concentrations of HAA/OHK in whole blood cultures from patients 
with major depression and healthy controls after incubation of cultures under different con-
ditions. Bars (Control, Depression) show the concentrations in the two study groups and 
error bars correspond to 95% confidence intervals. 
 
The next step in the enzymatic conversion towards QUIN is expressed by the 
HAA/OHK ratio. In this step, the mean ratio was also higher in the controls. No 
significant differences in the HAA/OHK ratio were found in any of the conditions 
with either with the t-test or in the univariate analysis of variance (Fig.15). 
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Figure 16: Ratio of mean concentrations of KYNA/OHK in whole blood cultures from pa-
tients with major depression and healthy controls after incubation of cultures under differ-
ent conditions. Bars (Control, Depression) show the concentrations in the two study groups 
and error bars correspond to 95% confidence intervals. 
 
We used the ratio KYNA/OHK to examine the ratio betw en the neuroprotective 
metabolite KYNA and the neurotoxic metabolite OHK. The mean ratios of 
KYNA to OHK were higher in the control than in the patient group across all cul-
ture conditions. The data showed no significant differences in either the t-test or in 
the univariate analysis of variance (Fig.16). 
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3.4 Summary of the results 
 
 
 
Figure 17: Graphical summary. Whole blood cultures from depressed patients and controls 
were first treated in vitro either without stimulat ion or with LPS and then different antide-
pressants or celecoxib were added. Cytokines and tryptophan pathway metabolites were 
measured. Up arrow indicates elevated levels either in controls (blue) or in patients (red). 
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4 Discussion  
 
Several lines of evidence point out the important role of the pro-inflammatory 
immune process in the pathophysiology of depression. Moreover, several in vivo 
and in vitro studies have demonstrated a modulating effect of antidepressant drugs 
on the immune system. On the other hand, clinical tri ls have shown the antide-
pressant effect of anti-inflammatory drugs like cele oxib. The missing link in un-
derstanding the mechanism was the proposed translation of immune signals into 
neurotransmitter changes as the physiological basis of altered mood states. The 
kynurenine pathway provides several functional links between pro- and anti-
inflammatory cytokines on the one hand and the neuroactive tryptophan pathway 
intermediates including serotonin and some kynurenine metabolites on the other 
hand. Using in vitro stimulated peripheral immune cells, the aim of this study was 
to investigate the effect of antidepressants and celecoxib on the production of pro- 
and anti-inflammatory cytokines and on the formation f kynurenine pathway 
intermediates. 
 
 
4.1 Cytokines 
 
As part of our research project we investigated changes in cytokines by examining 
whole blood cultures from depressed patients and healthy controls before and after 
stimulation with LPS and antidepressants. Some antidepressants influence the 
proinflammatory immune state in depressive disorders. The enzyme IDO metabo-
lizes TRP to KYN, and KYN is then converted to 3HK by the enzyme kynurenine 
hydroxylase, through which the metabolite QUIN is formed later. Both enzymes 
are induced by the T-helper type 1 cytokine IFNγ and inhibited by type 2 cyto-
kines such as IL-4.  
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In our study, the production of the proinflammatory cytokine IFNγ in response to 
immune challenge increased more in controls than in patients. Kim and co-
workers made the same observation in an in vitro study (Kim et al., 2007). IFNγ 
response was lowered only by celecoxib and only in cultures from healthy con-
trols while this reversal was not observed in the patients. This lower production of 
cytokines in response to LPS stimulation indicates immune cell exhaustion, which 
means that patients´ cells might have been in an LPS-refractory phase induced by 
a pro-inflammatory state, as described for endotoxin tolerance (Biswas et al., 
2009). We also found that IFNγ was increasing with venlafaxine in the cultures 
from control´s group and did not change in the patients` blood. In contrast to other 
studies (De Berardis et al., 2010) we couln´t support the notion that venlafaxine 
influences the proinflammatory cytokine secretion in patients.  
 
Stimulation with LPS enhanced production not only of IFNγ but also of the anti-
inflammatory cytokines IL-4 and IL-10. Production icreased significantly more 
in controls than in patients. However, this significant difference no longer existed 
when the cells were treated with imipramine and celecoxib. This indicates that the 
medications imipramine and celecoxib could reverse the abnormal response in the 
blood cells of the patients. Strong evidence of an immunosuppressive effect of 
imipramine was also demonstrated by Szuster-Ciesielka, who found that 
imipramine decreased the production of proinflammatory cytokines (IL-2, IL-4, 
IFNγ, and IL-12) while it stimulated anti-inflammatory cytokines (IL-10 and 
TGF-β) (Szuster-Ciesielska et al., 2003). Also Kubera et al. found that several 
antidepressant compounds – including imipramine, venlafaxine, 1-5-
hydroxytryptophan and fluoxetine – increased production of the anti-
inflammatory cytokine IL-10 and reduced the INF-γ/IL-10 ratio significantly 
(Kubera et al., 2000a). Taken together, we can expect that patients were rather in a 
proinflammatory state, which was mainly due to a reduction in anti-inflammatory 
signals and not to enhanced proinflammatory signals. 
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Several mechanisms have been proposed for the depressogenic action of cyto-
kines, including the induction of extrahypothalamic CRF and vasopressin, the 
development of glucocorticoid resistance, the activtion of IDO, and the increased 
expression of the serotonin transporter (Miller, 2009, Miller, 2008). Many studies 
show that treatment with cytokines results in depressive mood changes. Another 
hypothesis as to why a pro-inflammatory state could result in depression is the 
neurodegeneration hypothesis of depression, which proposes a cytokine-induced 
imbalance in kynurenine metabolites as part of the pathophysiological process  
(Myint et al. 2003). 
 
In the publication of their study, Kim et al. (2007) wrote that many research pro-
jects try to find biomarkers that predict the formation, development and, in the 
best case, remission of a depressive illness. This was also the aim of our study. 
Numerous studies have been published on the association between depression and 
immune and cytokine function. However, fewer have investigated the function of 
cytokines in the response of depression to antidepressant medications. After 
treatment, we would logically expect cytokine levels to normalize and the depres-
sive episode to resolve. However, a recent meta-analysis by Hannestad and co-
workers contradicted this idea (Hannestad et al., 2011). Although on the one hand 
they confirmed elevated levels of circulating proinflammatory cytokines, on the 
other they showed that antidepressant drugs do not have a significant effect on 
serum levels of cytokines. Their results are not fully comparable to ours because 
they analysed TNFα, IL-1β and IL-6, which were chosen because they are ele-
vated in depression (Dowlati et al., 2010, Howren et al., 2009). Thus, these au-
thors concluded that proinflammatory cytokines contribu e to depressive symp-
toms and that normalization of cytokine levels is not associated with remission. 
Maes et al. (2011) may have an explanation for this p enomenon. In their study, 
they showed that this missing effect of the drugs might be associated with auto-
immune responses directed against 5-HT. The incidene of anti-5-HT-antibody 
positivity is significantly higher in depressed patien s, regardless of whether or not 
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the patients were medicated. Contradictory to the satement made by Hannestad et 
al. (2011), Janssen et al. (2010), who reviewed the sci ntific literature from the 
past 20 years, found that antidepressants appear to normalize serum levels of cy-
tokines, especially TNFα, INF-γ, IL-6 and IL-1β.  
Generally, it is important to note that a multiplicity of medications act differently 
on a multiplicity and heterogeneity of cytokines. Many facts need to be studied in 
more detail. For example, inflammatory genes and cytokine genes represent a new 
target for research because of different genetic variants. A study investigated the 
association between genetic variants of the IL-1β gene and amygdala and anterior 
cingulate cortex responsiveness to emotional stimuli and response to antidepres-
sant treatment (Baune et al., 2010). It is also establi hed that there is a link be-
tween genetic variants and response to medical treatment. Yu et al. (2003) for 
example found that patients with MD who were homozygous for the -511T allele 
of the IL-1β gene had a trend towards less severity of depressive ymptoms and 
were more favorable for therapeutic response to fluxetine than -511C carriers. 
Such research may also enhance the understanding of the pathogenesis of MD. 
Intracellular signalling pathways are another focus for future research because 
they are responsible for cytokine activity. Specific receptors and enzymes are im-
portant for the complex chain reaction in cytokines and modulate their actions. 
Not only the variety and function of cytokines need to be studied further but also 
the mechanism of antidepressant effect on cytokine fu ction. Some in vitro stud-
ies indicate that antidepressants may inhibit proinflammatory cytokine activity 
through their effects on intracellular cyclic adenosi e monophosphate (cAMP). 
An increase in cAMP levels in different peripheral blood mononuclear cells 
(PBMC) leads to a decrease in proinflammatory cytokine levels (Hashioka et al., 
2007). Moreover, anti-inflammatory cytokines are up-regulated through the same 
mechanism. For example, higher cAMP levels increase the expression of IL-10 
mRNA and intracellular IL-10 in monocytes (Maes, 2001). Another mechanism 
for the effects of antidepressant drugs may be through influencing 5-HT levels. 
Peripheral 5-HT is not only present in brain and gut, b t is also stored in platelets 
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and immune cells like T-cells, monocytes or mast cells. T lymphocytes express 5-
HT receptors as well as high affinity 5-HT transporters (Aune et al., 1994). Recent 
studies have revealed effects of 5-HT on innate immune cells: Kushnir-Sukhov et 
al. (2006) described that 5-HT induces adhesion and chemotaxis in mast cells. 
Boehme et al. (2004) revealed for the first time an important role in eosinophil 
migration to the lung. Nakamura et al. (2008) showed that 5-HT enhanced phago-
cytosis in murine macrophages. Further there is evidence that 5-HT alters the cy-
tokine profile of dentritic cells, increasing IL-1β and IL-8 and decreasing IL12 
and TNF-α (Muller et al., 2009).  So, generally these authors revealed diverse 
roles for 5-HT in immune functions. This may be another target for antidepressant 
medications, that has to be explored in further studies. 
As explained in the introduction, the HPA axis is well known to be more active in 
depressed patients. The normal task of glucocorticoids is to inhibit the production 
of inflammatory cytokines. This inhibition seems to be disturbed in both acute 
depressive episodes and chronic depression. Studies show that cortisol and proin-
flammatory cytokine levels are increased in depression; this can be interpreted as 
a dysregulation of the HPA-axis feedback mechanism, i.e. higher levels of periph-
eral corticosteroids appear unable to stop the production of proinflammatory cyto-
kines in MD (Pace et al., 2007, Fitzgerald et al., 2006).  
 
 
4.2 Tryptophan metabolites 
 
As described in the introduction, tryptophan catabolites may have detrimental 
effects. Different mechanisms may explain how the metabolites work in the brain. 
First, metabolites like 3HK induce the production of radical oxygen species, 
which can cause mitochondrial dysfunction and influence energy metabolism. 
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Second, QUIN is a NMDA-receptor agonist with a potency to exert neurotoxic 
effects through induction of excitotoxicity (Stone et al., 1981). Effects of the cata-
bolites include the destruction of postsynaptic elements, degeneration of nerve 
cells – such as hippocampal cell death – and a reduction in cerebral cholinergic 
circuits (Maes et al., 2011, Maes et al., 2010). Because of these detrimental ef-
fects, the catabolites may be possible biomarkers for depression and for changes 
in depression during medical treatment. Many studies have shown a connection 
between MD and changes in tryptophan metabolism. 
 
In our study, TRP levels decreased after LPS stimulation. This could be due to a 
higher level of IFNγ, which increases IDO activity (IDO degrades TRP). We also 
found an increased level of KYN after inflammatory stimulation. KYN is again 
metabolized either via the toxic quinolinic pathway, in which 3HK, 3HAA and 
finally QUIN are produced, or via the kynurenic acid pathway, in which neuropro-
tective KYNA is the final metabolite. In accordance with the fact that IFNγ also 
activates KMO (Yasui et al., 1986), which degrades KYN to 3HK, we also found 
increased levels of 3HK.  
 
HAA levels decreased in patients and controls after s imulation with LPS, al-
though changes were not significant. There are two possible explanations for the 
reduction in HAA levels:  
 
a) KYNase is suppressed by the proinflammatory state, hus  less 3HK is con-
verted to HAA, or 
b) proinflammatory states activate the enzyme HAAO, which converts more 
HAA into QUIN, so that HAA levels decrease. 
 
AA levels also increased after LPS stimulation. This means that kynurinase en-
zyme activity cannot have been suppressed by a proinflammatory state. Therefore, 
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the low HAA level after LPS stimulation must have been due to increased activity 
of HAAO, resulting in an increased transformation of HAA into QUIN. 
 
Although cytokine changes are well documented in depression, the role of trypto-
phan metabolism in terms of the balance between neuroprotection and neurode-
generation in MD has not yet been fully explored. Studies have provided evidence 
that 3HK causes neuronal apoptosis (Okuda et al., 1998) and that QUIN causes 
excitotoxic neurodegenerative changes (Schwarcz et al., 1983). In contrast, KYN 
can also be metabolized into KYNA, an NMDA receptor antagonist (Perkins et 
al., 1982) that acts protectively against the excitotoxic action of QUIN (Stone et 
al., 2002). However, the importance of the tryptophan catabolites in vivo may be 
diminished by the finding that the concentrations achieved were significantly 
lower than those that would be needed to impair the viability of neurons (Stone, 
1993, Moroni, 1999).  
 
Since more KYN is formed after LPS stimulation, KYNA levels also increased. 
Across all the culture conditions, KYNA levels were numerically lower in patients 
than in the healthy controls, although none of the diff rences was statistically sig-
nificant. In line with our findings, Myint et al. (2007b) reported significantly 
lower plasma KYNA levels in depressed patients. Thus, it is suggested that in 
depression, the metabolism of KYN is preferentially directed into the quinolinic 
pathway. In contrast to our study, the patients in Dr. Myint`s study were medica-
tion naïve or medication free whereas our patients were receiving medication, and 
Myint et al. investigated plasma levels whereas we us d whole blood culture su-
pernatant. Moreover, that study had a higher statistical power due to a higher 
number of patients and controls. Because of the relativ y small sample size, our 
study may have been under-powered, which might explain the missing signifi-
cance of our findings. 
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4.3 The ratios of tryptophan metabolites 
 
The tryptophan breakdown index was generally numerically higher in the stimu-
lated condition, although the difference was not sta i tically significant. This ef-
fect can be explained by induction of IDO activity b  proinflammatory cytokines.   
 
In the basal, unstimulated condition, the healthy controls showed higher KYNA 
levels in terms of the ratio to KYN. This finding is in accordance with the findings 
of Myint et al. (2007a) who also found a higher ratio in the plasma of healthy con-
trols than in unmedicated depressed patients. After LPS stimulation, this differ-
ence in the ratio was no longer present and the values of the ratio decreased. This 
indicates that even though both KYNA and KYN levels are increased after LPS 
stimulation, less KYN is transformed into KYNA. The KYNA/KYN ratio is in-
terpreted as an index of neuroprotection. Thus, the reduced conversion into 
KYNA, which is a neuroprotective metabolite, may contribute to an imbalance in 
the neuroprotective and neurodegenerative pathways. Wichers and coworkers 
were the first to examine the increases in the neurotoxic potential of tryptophan 
catabolites. The development of depressive symptoms was significantly associated 
over time with the KYN/KYNA ratio, which reflects an increase in neurotoxic 
potential (Wichers et al., 2005). This finding is al o in agreement with the find-
ings of a study in hepatitis C patients in which the neurotoxic challenge was 
higher when patients were treated with IFNα  and subsequently developed of de-
pressive symptoms (Wichers et al., 2005). In contrast, Van Gool et al. (2008) did 
not find that an increased production of neurotoxic metabolites was associated 
with the development of depressive symptoms during IFNα therapy. 
We also found that the ratio 3HK/KYN decreased after LPS stimulation, although 
both 3HK and KYN levels increased. This ratio was higher in the patients. More-
over, the ratio of HAA/3HK was also reduced after LPS stimulation. 
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Similar to the findings of other studies, our data demonstrate that the further cata-
bolization of 3HK beyond HAA into QUIN may be significantly induced in the 
inflammatory state. Our finding thus supports the neurodegenerative hypothesis of 
depression of Myint et al. (2003), which proposes that an accumulation of neuro-
toxic QUIN might be involved in the physiology of depression. Unfortunately, in 
our series of experiments QUIN was not quantified. So we can´t confirm wether 
there would have been significant results. This needs to be included in further 
projects. 
 
We also found that the KYNA/3HK ratio was lower in the unstimulated cultures 
of patients across all culture conditions, which indirectly indicates that there is an 
imbalance between KYN metabolites in depressed patients. 
 
 
4.4 Anti-inflammatory effects of medications and new drug targets  
 
Our findings of altered IL-10 production may help to explain the beneficial thera-
peutic effect of celecoxib in depressed patients as reported by Müller and col-
leagues who found that celecoxib add-on therapy to standard antidepressants re-
sulted in better treatment response in depressed patients (Muller et al., 2006). In 
our experiments, celecoxib enhanced the production of the anti-inflammatory cy-
tokine IL-10 and abolished the statistically significant difference from the healthy 
controls. According to our findings, this beneficial clinical effect of the COX2 
inhibitor celecoxib might be mediated through enhanced production of the anti-
inflammatory cytokine IL-10. Since prostaglandin E2, a product of COX2, is in-
volved in cytokine production, inhibition of the COX2 enzyme might have a 
beneficial effect on the inflammatory status in depressed patients. In addition to 
the effect on IL-10, celecoxib antagonized the numerical LPS-induced increase of 
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IFNγ production in the blood cultures of healthy controls. This modulating proc-
ess was not seen in the culture derived from patients. Therefore, in healthy sub-
jects celecoxib appears to have additional beneficial effects via suppression of a 
proinflammatory reaction, while this effect is blocked in depressed patients. For 
understanding, why the cells of depressed patients didn´t react in the same way 
like the controls, the intracellular signaling pathways need to be analysed more 
and may serve as new targets for future research. 
 
Regarding the findings of IL-10, imipramine showed similar effects to celecoxib. 
There was an numerical increase of the IL-10 concentration in depressed patients 
and could therefore be beneficial in terms of re-balancing the immune function 
and eventually reversing the inflammatory response seen in depression. This find-
ings may be supported by other authors, like Kubera et al. (2001), who found sig-
nificantly increased production of IL-10 incubation with imipramine. The antide-
pressant-induced changes were detectable in IL-10 and IFNγ for both groups 
without difference between patients and controls, which may be due to methodo-
logical differences such as incubation time and medication status of the patients. 
Also Himmerich et al. (2010) identified tricyclic antidepressants like imipramine 
to suppress proinflammatory cytokines in in vitro exp riments with blood from 
patients suffering from MD. Therefore, as in this study, imipramine could lead to 
a dominance of anti-inflammatory cytokines. Although on the basis of our data we 
cannot explain the mechanism of action of imipramine o  IL-10, our results un-
derline the evidence for imipramine having beneficial effects on the inflammatory 
status in depression.  
 
Celecoxib did not affect LPS-induced changes in tryptophan metabolites. Since 
whole blood culture contains different types of cells, the culture of specific im-
mune cells may give a clearer answer. 
Apart from medications that influence the inflammatory state in depressed pa-
tients, several possible pharmacological targets remain as topics for further re-
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search. For example, inhibitors of the activities of the enzymes along the KYN 
pathway may be able to counteract the detrimental effects. Another strategy may 
be to antagonize the possible neurotoxic effects by increasing the systemic protec-
tive effects of KYNA through blockade of the organic acid transporter by pro-
benecid (Carrillo-Mora et al., 2010). Wang et al. (2009) found that LPS may in-
duce IDO via IFNγ-independent mechanisms. Thus, the blockade of LPS-induced 
IDO expression may be an interesting topic for future research. Other studies 
found a glia-depressing factor, which might have a significant impact not only on 
the regulation of KYNA metabolism but also on the regulation of glia/astroglia 
activity and glia proliferation (Baran et al., 2010). The synthesis of this factor is 
increased by the inflammation-induced activation of microglia. This suggests that 
microglia activity and the associated increased synthesis of glia-depressing factor 
are novel drug targets that may dampen neuroinflammtion in depressed patients. 
Specific antioxidants may also be possible pharmacological targets. Epigallocate-
chin-3 gallate is a component of green tea that mayattenuate the activation of 
inflammatory, oxidative and nitrosative stress pathways in mice brains (Sachdeva 
et al., 2010) and that has neuroprotective effects against QUIN-induced excitotox-
icity (Jang et al., 2010). Other projects concentrate on direct inhibitors of IDO, 
like norharman, which counteracts IDO activation and attenuates the neurotoxic 
consequences (Eggers et al., 2004). However, this finding should be interpreted 
carefully because these treatments could also abrogte the antiproliferative and 
antioxidative effects of IDO activation, possibly resulting in negative feedback. 
As explained, many different pathways are involved in epression, so the devel-
opment of novel antidepressants should include not o ly inflammation and sero-
tonin but also the catabolism of tryptophan and neurogenesis.  
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4.5 General and methodological limitations 
 
This study has some general and methodological limitations. The general limita-
tion is the fact that the in vitro data may not reflect the in vivo situation since cells 
isolated outside the body are detached from the internal influences of homeostasis 
mechanisms. The use of cell cultures and the stimulation and subsequent meas-
urement of cytokines or metabolites are very common, according to the multifari-
ous protocols for cell culture experiments. Many studies have been performed 
with purified cells or cell lines but fewer with whole blood (Yaqoob et al., 1999). 
Cell isolation processes, which are needed for PBMCs, may not only damage cells 
but also require conditions that are less like physiological  conditions. On the 
other hand, the conditions in whole blood cultures are also not equivalent to those 
in vivo and the number of cells cultured is neither known nor controlled (Yaqoob 
et al., 1999). The variability and levels of cytokines in isolated PBMC are larger 
than in whole blood cultures. Therefore, it is more difficult to reach significant 
levels and the variation may be increased. Theoretically, cell cultures can be fur-
ther isolated. For example, culturing monocytes for 24 hours results in the genera-
tion of a population of veiled accessory cells (Ruwhof et al., 2002), which are 
further dissociated from the in vivo condition. 
 
Another factor that may explain why only a few results were significant is the 
concentration of our antidepressant medications. We wanted to simulate the in 
vivo situation as realistically as possible and therefore we used concentrations in a 
therapeutic range. If the concentrations had been higher, the measurements might 
have been clearer. However, to our knowledge there is no evidence in the litera-
ture for different results concerning the application of different concentrations.    
 
Regarding the method for determination of cytokine levels, we chose Luminex® x 
MAP technology®, a capture/detection sandwich type immunoassay, for the quan-
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titative analysis of cytokines. An earlier study compared three different available 
multiplex kits with each other and with enzyme-linked immunosorbent assay 
(ELISA), the “gold standard” of protein quantification (Djoba Siawaya et al., 
2008). This study also took the supernatants of stimulated whole blood cultures. 
The great advantage of the Luminex system is the possibility to analyse up to 100 
different microsphere sets in a single 50 µl sample. Siawaya et al. concluded that 
the Luminex technology is a good screening tool for the selection of markers but 
that promising candidates can then be validated using ELISA with higher accu-
racy and proven reliability (Djoba Siawaya et al., 2008). In principle, this me-
thodical procedure corresponds to our study design. 
 
Another possible confounder of our results may be the subjects’ cortisol levels. 
Cortisol can influence the immune system and affects the KYN pathway through 
activation of tryptophan 2,3-dioxygenase (TDO), resulting in enhanced TRP 
breakdown to KYN (Young, 1981). Several studies have shown that depressive 
patients have increased cortisol secretion, even throug out the day. This finding 
was confirmed by Piwowarska et al. (2009); however, other studies did not obtain 
the same results (Posener et al., 2000, Young et al., 2001). In our study, blood was 
always taken before ten in the morning to reduce cortisol influences. The actual 
cortisol level of each participant was not measured, so that we cannot make a 
statement about how cortisol concentrations may have affected our data. 
 
Another limitation was the relatively small sample size. A high heterogeneity in 
the small population of patients might have contributed to the high degree of 
variation in the data. The small sample size, in addition to the confounding fac-
tors, might also explain why we found only numerical differences that did not 
reach statistical significance. In their systematic review, Janssen et al. (2010) 
found that a strong immunosuppressive effect is more pronounced when PBMCs 
are used rather than whole blood samples, although the whole blood cultures used 
in our study design reproduced the in vivo situation more realistically. However, 
 68
for statistical analysis the data become less significa t and gain variance. How-
ever, neither of these methods simulates true biological processes. Although both 
methods are established standards in immunological research, care needs to be 
taken when extrapolating from study conditions to th se in humans. Moreover, 
the patients were being treated with antidepressant medications and were in a sta-
ble state at the time of sample collection.  
 
Nevertheless, this study demonstrated imbalances in the immune system and tryp-
tophan metabolism in stable depressed patients receiving antidepressant mono-
therapy.  
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5 Summary 
 
Numerous studies have described the influence of the immune system to the 
pathophysiology of depressive disorders and shown that there is an activation of 
the pro-inflammatory immune system in depressive state. Characteristics of this 
immune activation are increased synthesis of proinflammatory cytokines and an 
increased numbers of lymphocytes and phagocytic cells. These cytokines change 
in tryptophan metabolism, the activity of the key-enzyme indoleamine 2,3-
dioxygenase (IDO). Tryptophan (TRP), the precursor of serotonin is catabolized 
by IDO to kynurenine (KYN), which releases in the further degradation cascade at 
least three neuroactive intermediates. The close functional relationship between 
the effects of cytokines and the TRP-KYN metabolism  the basis for the central 
role of kynurenine in depressive disorders. Since IDO is ubiquitously present in 
the human body, the peripheral blood mononuclear cells (PBMC) form a 
representative model, which allows inferences about intracerebral processes. The 
hypothesis of this dissertation is that inflammatory p ocesses result in elevated 
concentrations of the metabolites of TRP-KYN metabolism and thereby affect 
cerebral processes. These metabolites may represent biomarkers of depressive 
disorders. Another aspect is the observation that various antidepressants can 
change a present pro-inflammatory immune status into an anti-inflammatory 
immune status. 
This study examines the effect of different antidepressants (reboxetine, fluoxetine, 
venlafaxine, imipramine) and the COX-2 inhibitor celecoxib on the immune 
system and the metabolism of tryptophan. This was done in mitogen-stimulated 
and unstimulated whole blood cultures of 21 depressiv  patients and 80 healthy 
control subjects. The whole blood was cultured in 24-well plates and stimulated 
with lipopolysaccharide (LPS). The proinflammatory c tokine IFNγ, the anti-
inflammatory cytokines IL-4 and IL-10 and tryptophan metabolites were analyzed 
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in the supernatants of stimulated and unstimulated cultures. These measurements 
were made using Luminex and HPLC methods. 
The results show that the immune response through the synthesis of 
proinflammatory IFNγ - and anti-inflammatory IL-4 and IL-10 in the control 
group was significantly higher compared to the group f patients. This significant 
difference was repealed by treatment with imipramine a d celecoxib. This allows 
the conclusion that these drugs may antagonize the abnormal immune response of 
mitogen-stimulated cells in depressive patients. In all patients` blood cultures, the 
metabolites of tryptophan metabolism showed decreased TRP levels, increased 
KYN levels and reduced concentrations of 3-hydroxy-anthranilic acid (HAA). 
The concentration of KYNA tended to be higher in all cultures of the control 
group compared to the group of patients, but this difference was not significant. In 
the unstimulated conditions the controls showed higher KYNA values in relation 
to the ratio of KYN. After LPS stimulation this difference in the ratio of 
KYNA/KYN (index for neuroprotection) has been repealed. After stimulation, the 
ratio 3HK/KYN decreased despite the increase in 3HK and KYN levels. This ratio 
showed increased values in all patient cultures. The study also showed that the 
ratio of KYNA/OHK in patients with unstimulated samples was lower in 
comparison to all other culture conditions. This observation indicates indirectly 
the inter-individual imbalance of KYN metabolites in depressed patients. 
The observation of increased expression of antiinflammatory IL-10 under 
antidepressant therapy emphasizes the positive effect of celecoxib. For 
imipramine a similar effect was observed. 
In summary, the results of this study give new approaches for future research 
projects, which analyse the interaction of antidepressant therapy with the immune 
system and the metabolism of tryptophan in depressiv  illness. 
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6 Zusammenfassung 
 
Zahlreiche Studien haben den Einfluss des Immunsystems auf die Pathophysiolo-
gie depressiver Erkrankungen beschrieben und gezeigt, dass bei depressiven Stö-
rungen ein proinflammatorischer Immunstatus vorliegt. Charakteristisch für diese 
Immunaktivierung sind eine vermehrte Ausschüttung proinflammatorischer 
Zytokine sowie eine vermehrte Synthese von Lymphozyten und phagozytierenden 
Zellen. Diese Zytokine verändern im Tryptophanstoffwechsel die Aktivität des 
Schlüsselenzyms Indolamin 2,3-dioxygenase (IDO). Tryptophan (TRP), der Vor-
läufer des Serotonins wird durch IDO zu Kynurenin (KYN) katabolisiert, welches 
in der weiteren Abbaukaskade mindestens drei neuroaktive Zwischenprodukte 
freisetzt. Der enge funktionelle Zusammenhang zwischen den Zytokineffekten 
und dem TRP-KYN-Metabolismus ist die Basis für die z ntrale Rolle des 
Kynurenins bei depressiven Störungen. Da die IDO im menschlichen Körper ubi-
quitär vorhanden ist, bilden mononukleäre Zellen des p ripheren Blutes (PBMC) 
ein repräsentatives Modell, welches Rückschlüsse auf intracerebrale Prozesse er-
laubt. Die Hypothese dieser Arbeit ist, dass Metabolite des TRP-KYN-
Stoffwechsels aufgrund inflammatorischer Prozesse in erhöhter Konzentration 
entstehen und hierdurch cerebrale Vorgänge beeinflussen. Diese Metabolite kön-
nen Biomarker depressiver Störungen darstellen. Ein weiterer Aspekt ist die Be-
obachtung, dass verschiedene Antidepressiva einen vorliegenden 
proinflammatorischen Immunstatus in eine antiinflammatorischen umwandeln 
können. 
Diese Studie untersucht die Wirkung verschiedener Antidepressiva (Reboxetin, 
Fluoxetin, Venlafaxin, Imipramin) sowie des COX-2-Inhibitors Celecoxib auf das 
Immunsystem und den Tryptophan-Stoffwechsel. Dies erfolgt in mitogen-
stimulierten und unstimulierten Vollblut-Kulturen von 21 depressiven Patienten 
und 80 gesunden Kontrollpersonen. Das Vollblut wurde in 24-Well-Platten kulti-
viert und mit Lipopolysaccharid (LPS) stimuliert. Das proinflammatorische 
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Zytokin IFNγ, die antiinflammatorischen Zytokine IL-4 und IL-10 und die 
Tryptophan-Metabolite wurden in den Überständen von stimulierten und 
unstimulierten Kulturen analysiert. Diese Messungen erfolgten mittels Luminex- 
und HPLC-Verfahren.  
Die Ergebnisse zeigen, dass die Immunantwort durch die Synthese von 
proinflammatorischem IFNγ - und antiinflammatorischer IL-4 und IL-10 bei der 
Kontrollgruppe signifikant höher im Vergleich zur Patientengruppe war. Dieser 
signifikante Unterschied wurde durch die Behandlung mit Imipramin und Celeco-
xib aufgehoben. Dies ermöglicht die Schlussfolgerung, dass diese Medikamente 
die abnorme Immunantwort mitogen-stimulierter Zellen depressiver Patienten 
antagonisieren können. Die Metabolite des Tryptophan-Stoffwechsels zeigten in 
allen Blutkulturen der Patientengruppe verminderte TRP-Level, erhöhte KYN-
Level und verringerte Konzentrationen der 3-Hydroxy-Anthranilsäure (HAA). Die 
KYNA Konzentration war in allen Kulturen der Kontrollgruppe tendenziell höher 
im Vergleich zur Patientengruppe; dieser Unterschied war jedoch nicht signifi-
kant. In den unstimulierten Konditionen zeigten dieKontrollen höhere KYNA-
Werte in Bezug auf das Verhältnis zu KYN. Nach der LPS-Stimulierung wurde 
der Gruppenunterschied des Quotienten KYNA/KYN (Index für Neuroprotektion) 
aufgehoben. Nach der Stimulation verminderte sich trotz der Erhöhung der 3HK- 
und KYN- Level das Verhältnis 3HK/KYN. Dieses Verhältnis zeigte in allen Pa-
tientenkulturen erhöhte Werte. Die Studie zeigte auch, dass der KYNA/OHK 
Quotient bei Patienten mit unstimulierten Proben niedriger im Vergleich zu allen 
anderen Kulturbedingungen war. Diese Beobachtung zei t indirekt das inter-
individuelle Ungleichgewicht der KYN- Metaboliten bei depressiven Patienten. 
Die Beobachtung der gesteigerten Exprimierung des antiinflammatorsischen IL-
10 unter Antidepressiva-Therapie unterstreicht die positive Wirkung von Celeco-
xib. Auch für Imipramin wurde ein ähnlicher Effekt beobachtet. 
Zusammenfassend liefern die Ergebnisse dieser Studie neue Ansätze für zukünfti-
ge Forschungsprojekte, welche die Interaktion antidepressiver Therapien mit dem 
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Immunsystem und dem Tryptophan-Metabolismus depressiver Erkrankungen 
anaylsieren. 
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II.   Abbreviations 
 
AA   Anthranilic acid 
ACTH   adrenocorticotropin 
cAMP  cyclic adenosine monophosphate 
BMI   body mass index 
COX   cyclooxygenase 
CNS   central cervous system 
CRH   cortisol-releasing-hormone 
DSM   diagnostic and statistical manual of mental disorders 
ELISA  enzyme-linked immunosorbent assay 
cGMP  cyclic guanosine monophosphate 
HAA   3-hydroxy- anthranilate 
HAAO  3-hydroxy anthranilate oxygenase 
HAMD  Hamilton Depression Scale 
HPA axis  hypothalamus-pituitary-adrenal axis 
HPLC  high pressure liquid chromatography 
HPT axis  hypothalamus-pituitary-thyroid axis 
5-HT   serotonin 
ICD  international statistical classification of diseases and related 
health problems 
IDO   indoleamine 2,3-dioxygenase 
IFN   interferon 
IL   interleukin 
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KYN   kynurenine 
KYNA  kynurenic acid 
LMU   Ludwig-Maximilians Universität 
LPS   lipopolysaccharide 
MARDS  Montgomery-Asberg Depression Rating Scale 
MAOI  monoamine oxidase inhibitor 
MD   major depression 
M.I.N.I.  mini international neuropsychiatric interview 
NAD   nicotinamide andenine dinucleotide 
NMDA  N-methyl-D-aspartate 
OHK= 3HK 3-hydroxy-kynurenine 
PBMC  peripheral blood mononuclear cells 
PGE2  prostaglandin E2 
PSS   perceived stress scal 
QUIN  quinolinic acid 
SNRI   selective noradrenaline reuptake inhibitor 
SSNRI  selective serotonin-noradrenaline reuptake inhib tor 
SSRI   selective serotonin reuptake inhibitor 
TCA   tricyclic antidepressant 
TDO   tryptophan 2,3-dioxygenase 
TNF   tumour necrosis factor 
TRH   thyrotropin releasing hormone 
TRP   tryptophan 
TSH   thyroid stimulating hormone 
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UPLC-MS  ultra performance liquid chromatography and mass spectrometry 
WHO  world health organisation 
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